BHVNNYSEPharmaceutical PreparationsFiscal year ends December 31
Biohaven Ltd.
Financials through Q2 FY2026, quarter ended Jun 30, 2026Last filing: 10-Q on Aug 10, 2026
$11.35+0.57 (+5.29%)
Close on Oct 19, 2026
- Market cap
- $1.71B
- P/E (TTM)
- –
- Dividend yield
- –
Ownership
Institutional holdings as of Jun 30, 2026, from 13F filings
Held by institutions
93.4%
141M of 151M shares
Institutional holders
294
52 new, 31 sold out
Net institutional buying
15M
In Q2 2026
Insider trades, 12 months
5 buys · 0 sales
Net bought $33.14M
Shares held by institutions
Holders of more than 5%
Latest Schedule 13D (active) or 13G (passive) filed by each holder
| Holder | Shares | % of class | Filing | As of |
|---|---|---|---|---|
| JANUS HENDERSON GROUP Ltd. | 8,584,676 | 5.70% | 13G (passive) amendment | Jun 30, 2026 |
| Woodline Partners LP | 7,660,280 | 5.10% | 13G (passive) | Jun 30, 2026 |
| BlackRock, Inc. | 5,762,738 | 7.20% | 13G (passive) | Dec 31, 2023 |
| Janus Henderson Group PLC | 17,534,612 | 11.70% | 13G (passive) amendment | Mar 31, 2026 |
| Suvretta Capital Management, LLC | 10,286,937 | 7.80% | 13G (passive) amendment | Dec 31, 2025 |
Top institutional holders
13F holdings as of Jun 30, 2026
| Holder | Shares | % of BHVN | Value | Change | % of portfolio |
|---|---|---|---|---|---|
| BlackRock, Inc. | 13,210,585 | 8.75% | $196.57M | +1,988,178 | 0.00% |
| Suvretta Capital Management, LLC | 10,286,937 | 6.81% | $153.07M | – | 2.80% |
| Stifel Financial Corp | 9,941,165 | 6.58% | $147.92M | +280 | 0.12% |
| Jupiter Topco LLC | 8,584,675 | 5.68% | $127.85M | New | 0.05% |
| Woodline Partners LP | 7,660,280 | 5.07% | $113.98M | +7,359,891 | 0.35% |
| State Street Corp | 6,947,034 | 4.60% | $103.37M | +328,231 | 0.00% |
| Infinitum Asset Management, LLC | 6,250,000 | 4.14% | $93.00M | – | 9.46% |
| D. E. Shaw & Co., Inc. | 4,190,195 | 2.77% | $62.35M | +1,343,002 | 0.03% |
| Aqr Capital Management LLC | 4,150,616 | 2.75% | $61.76M | +2,175,100 | 0.02% |
| Geode Capital Management, LLC | 3,323,190 | 2.20% | $49.46M | +555,427 | 0.00% |
| FMR LLC | 2,964,630 | 1.96% | $44.11M | +605,583 | 0.00% |
| Royalty Pharma Sub-Manager, LLC | 2,936,507 | 1.94% | $43.70M | – | 18.06% |
| Cormorant Asset Management, LP | 2,610,000 | 1.73% | $38.84M | +850,000 | 1.99% |
| Goldman Sachs Group Inc | 2,583,046 | 1.71% | $38.44M | +69,865 | 0.00% |
| UBS Group AG | 2,518,827 | 1.67% | $37.48M | +1,092,400 | 0.00% |
| Vanguard Portfolio Management LLC | 2,488,941 | 1.65% | $37.04M | +209,666 | 0.00% |
| Balyasny Asset Management L.P. | 1,879,734 | 1.24% | $27.97M | −565,682 | 0.03% |
| TCG Crossover Management, LLC | 1,779,952 | 1.18% | $26.49M | −2,851,365 | 0.64% |
| Nuveen, LLC | 1,744,334 | 1.15% | $25.96M | +998,586 | 0.01% |
| Rubric Capital Management LP | 1,721,493 | 1.14% | $25.62M | New | 0.23% |
Institutional buying and selling by quarter
Positions opened, added to, reduced and closed by 13F filers
| Quarter | Holders | Shares held | % of shares | New / added | Reduced / closed | Shares bought | Shares sold |
|---|---|---|---|---|---|---|---|
| Q2 2026 | 294 | 141M | 93.4% | 52 / 109 | 87 / 31 | 36M | 21M |
| Q1 2026 | 277 | 144M | 95.1% | 44 / 118 | 64 / 34 | 39M | 11M |
| Q4 2025 | 273 | 122M | 80.4% | 72 / 117 | 55 / 57 | 56M | 20M |
| Q3 2025 | 264 | 86M | 56.7% | 50 / 89 | 73 / 32 | 17M | 19M |
| Q2 2025 | 249 | 87M | 57.7% | 38 / 96 | 70 / 52 | 15M | 19M |
| Q1 2025 | 265 | 91M | 60.4% | 48 / 95 | 75 / 36 | 8M | 7M |
| Q4 2024 | 256 | 92M | 61.1% | 47 / 103 | 64 / 41 | 12M | 7M |
| Q3 2024 | 254 | 87M | 57.6% | 53 / 77 | 80 / 23 | 17M | 7M |
| Q2 2024 | 225 | 83M | 55.2% | 40 / 100 | 50 / 56 | 16M | 9M |
| Q1 2024 | 243 | 76M | 50.3% | 56 / 73 | 71 / 30 | 13M | 10M |
| Q4 2023 | 218 | 73M | 48.0% | 58 / 77 | 46 / 26 | 18M | 7M |
| Q3 2023 | 187 | 61M | 40.7% | 22 / 63 | 67 / 22 | 7M | 5M |
Top mutual fund and ETF holders
Latest monthly portfolio reports (Form N-PORT)
| Fund | Shares | % of BHVN | Value | % of fund | As of |
|---|---|---|---|---|---|
| Vanguard Extended Market Index Fund | 1,489,215 | 0.99% | $22.16M | 0.02% | Jun 30, 2026 |
| SMALLCAP World Fund Inc | 1,168,175 | 0.77% | $17.38M | 0.02% | Jun 30, 2026 |
| Nuveen Quant Small Cap Equity Fund | 826,340 | 0.55% | $11.16M | 0.27% | Jul 31, 2026 |
| Vanguard Russell 2000 Index Fund | 603,592 | 0.40% | $6.65M | 0.04% | May 31, 2026 |
| College Retirement Equities Fund - Total Global Stock Account | 508,214 | 0.34% | $7.56M | 0.01% | Jun 30, 2026 |
| Vanguard Strategic Equity Fund | 490,599 | 0.32% | $7.30M | 0.06% | Jun 30, 2026 |
| Vanguard Explorer Fund | 485,893 | 0.32% | $6.56M | 0.03% | Jul 31, 2026 |
| Vanguard Health Care Index Fund | 392,136 | 0.26% | $4.32M | 0.02% | May 31, 2026 |
| Nuveen Quant Small/Mid Cap Equity Fund | 382,100 | 0.25% | $5.16M | 0.19% | Jul 31, 2026 |
| Invesco RAFI US 1500 Small-Mid ETF | 236,037 | 0.16% | $3.19M | 0.12% | Jul 31, 2026 |
| Nuveen Small Cap Blend Index Fund | 176,731 | 0.12% | $2.39M | 0.06% | Jul 31, 2026 |
| Vanguard Strategic Small-Cap Equity Fund | 129,647 | 0.09% | $1.93M | 0.06% | Jun 30, 2026 |
| Direxion Daily S&P Biotech Bull 3X Shares | 128,814 | 0.09% | $1.74M | 0.35% | Jul 31, 2026 |
| Nuveen ESG Small-Cap ETF | 120,245 | 0.08% | $1.62M | 0.13% | Jul 31, 2026 |
| Vanguard Russell 2000 Growth Index Fund | 110,695 | 0.07% | $1.22M | 0.07% | May 31, 2026 |
Officers, directors and major owners
People who filed Forms 3, 4 or 5 in the last two years
| Name | Role | Shares owned | % of shares | Latest filing |
|---|---|---|---|---|
| Vlad Coric | Chief Executive Officer, Director | 3,856,784 | 2.55% | Mar 3, 2026 |
| Kimberly Gentile | SVP, Clinical Operations | 101,513 | 0.07% | Sep 17, 2026 |
| Warren Karl Volles | Chief Legal Officer | 248,212 | 0.16% | Jul 17, 2026 |
| George C. Clark | VP, Chief Accounting Officer | 86,978 | 0.06% | Mar 3, 2026 |
| Bruce Car | Chief Scientific Officer | 40,096 | 0.03% | Mar 3, 2026 |
| Matthew Buten | Chief Financial Officer | 198,246 | 0.13% | Mar 3, 2026 |
| John Yetimoglu | Director | 6,250,000 | 4.14% | Aug 14, 2026 |
| Gregory Bailey | Director | 2,020,071 | 1.34% | Apr 30, 2026 |
| John W. Childs | Director | 8,088,392 | 5.35% | Apr 30, 2026 |
| Kishan Mehta | Director | 22,662 | 0.02% | Apr 30, 2026 |
| Irina Antonijevic | Director | 2,535 | 0.00% | Apr 30, 2026 |
| Michael Thomas Heffernan | Director | 15,178 | 0.01% | Apr 30, 2026 |
| Robert J. Hugin | Director | 12,959 | 0.01% | Apr 30, 2026 |
| Julia P. Gregory | Director | 25,665 | 0.02% | Apr 30, 2026 |
Insider trades
Common stock transactions reported on Form 4, newest first
| Insider | Date | Transaction | Shares | Price | Value | Shares after |
|---|---|---|---|---|---|---|
| Kishan Mehta Director | Mar 17, 2026 | Gift | +17,342 | – | – | 17,342 |
| Kishan Mehta Director | Mar 17, 2026 | Gift | −17,342 | – | – | 5,320 |
| George C. Clark VP, Chief Accounting Officer | Jan 5, 2026 | Tax withholding | −1,117 | $9.93 | $11.09K | 66,978 |
| George C. Clark VP, Chief Accounting Officer | Jan 5, 2026 | Option exercise | +2,500 | – | – | 68,095 |
| Matthew Buten Chief Financial Officer | Jan 5, 2026 | Option exercise | +4,250 | – | – | 198,246 |
| Matthew Buten Chief Financial Officer | Jan 5, 2026 | Tax withholding | −2,594 | $9.93 | $25.76K | 195,652 |
| Kimberly Gentile SVP, Clinical Operations | Jan 5, 2026 | Option exercise | +3,750 | – | – | 101,513 |
| Kimberly Gentile SVP, Clinical Operations | Jan 5, 2026 | Tax withholding | −1,956 | $9.93 | $19.42K | 99,557 |
| Bruce Car Chief Scientific Officer | Jan 5, 2026 | Option exercise | +4,750 | – | – | 10,096 |
| Bruce Car Chief Scientific Officer | Jan 5, 2026 | Tax withholding | −2,381 | $9.93 | $23.64K | 7,715 |
| Vlad Coric Chief Executive Officer, Director | Jan 5, 2026 | Option exercise | +14,250 | – | – | 1,811,398 |
| Vlad Coric Chief Executive Officer, Director | Jan 5, 2026 | Tax withholding | −7,430 | $9.93 | $73.78K | 1,803,968 |
| George C. Clark VP, Chief Accounting Officer | Nov 17, 2025 | Buy | +17,000 | $8.52 | $144.84K | 20,000 |
| Vlad Coric Chief Executive Officer, Director | Nov 13, 2025 | Buy | +333,333 | $7.50 | $2.50M | 1,195,275 |
| Vlad Coric Chief Executive Officer, Director | Nov 13, 2025 | Buy | +333,333 | $7.50 | $2.50M | 740,546 |
| John W. Childs Director | Nov 13, 2025 | Buy | +3,333,333 | $7.50 | $25.00M | 5,653,904 |
| Gregory Bailey Director | Nov 13, 2025 | Buy | +400,000 | $7.50 | $3.00M | 2,020,071 |
| John W. Childs Director | Mar 4, 2025 | Buy | +28,400 | $30.43 | $864.21K | 2,323,971 |
| John W. Childs Director | Mar 4, 2025 | Buy | +25,000 | $30.39 | $759.75K | 2,320,571 |
| John W. Childs Director | Mar 4, 2025 | Buy | +3,400 | $30.73 | $104.48K | 24,452 |
| John W. Childs Director | Mar 4, 2025 | Buy | +3,400 | $30.73 | $104.48K | 76,570 |
| John W. Childs Director | Mar 4, 2025 | Buy | +900 | $30.73 | $27.66K | 25,291 |
| Vlad Coric Chief Executive Officer, Director | Jan 5, 2025 | Option exercise | +14,250 | – | – | 1,803,409 |
| Vlad Coric Chief Executive Officer, Director | Jan 5, 2025 | Tax withholding | −6,805 | $38.64 | $262.95K | 1,796,604 |
| George C. Clark VP, Chief Accounting Officer | Jan 5, 2025 | Option exercise | +2,500 | – | – | 66,168 |
| George C. Clark VP, Chief Accounting Officer | Jan 5, 2025 | Tax withholding | −1,117 | $38.64 | $43.16K | 65,051 |
| Bruce Car Chief Scientific Officer | Jan 5, 2025 | Option exercise | +4,750 | – | – | 7,133 |
| Bruce Car Chief Scientific Officer | Jan 5, 2025 | Tax withholding | −2,331 | $38.64 | $90.07K | 4,802 |
| Matthew Buten Chief Financial Officer | Jan 5, 2025 | Option exercise | +4,250 | – | – | 196,013 |
| Matthew Buten Chief Financial Officer | Jan 5, 2025 | Tax withholding | −2,561 | $38.64 | $98.96K | 193,452 |
| Kimberly Gentile SVP, Clinical Operations | Jan 5, 2025 | Option exercise | +3,750 | – | – | 99,719 |
| Kimberly Gentile SVP, Clinical Operations | Jan 5, 2025 | Tax withholding | −1,956 | $38.64 | $75.58K | 97,763 |
| John W. Childs Director | Dec 30, 2024 | Buy | +29,000 | $35.94 | $1.04M | 2,368,741 |
| John W. Childs Director | Oct 2, 2024 | Buy | +21,052 | $47.50 | $999.97K | 21,052 |
| Vlad Coric Chief Executive Officer, Director | Oct 2, 2024 | Buy | +21,052 | $47.50 | $999.97K | 861,942 |
| Gregory Bailey Director | Sep 24, 2024 | Buy | +5,000 | $44.19 | $220.95K | 1,620,071 |
| John W. Childs Director | Jul 18, 2024 | Buy | +28,400 | $35.67 | $1.01M | 2,339,741 |
| Bruce Car Chief Scientific Officer | Jun 17, 2024 | Buy | +30,000 | $33.58 | $1.01M | 30,000 |
| John W. Childs Director | May 30, 2024 | Buy | +28,000 | $35.58 | $996.24K | 2,311,341 |
| Gregory Bailey Director | May 13, 2024 | Buy | +15,000 | $34.19 | $512.85K | 1,615,071 |
| John W. Childs Director | May 13, 2024 | Buy | +28,500 | $35.17 | $1.00M | 2,283,341 |
| Gregory Bailey Director | Apr 24, 2024 | Buy | +25,503 | $39.18 | $999.21K | 1,600,071 |
| John W. Childs Director | Apr 22, 2024 | Buy | +73,170 | $41.00 | $3.00M | 73,170 |
| Vlad Coric Chief Executive Officer, Director | Apr 22, 2024 | Buy | +121,951 | $41.00 | $5.00M | 1,788,417 |
| John W. Childs Director | Apr 22, 2024 | Buy | +24,391 | $41.00 | $1.00M | 24,391 |
| John W. Childs Director | Apr 22, 2024 | Buy | +73,170 | $41.00 | $3.00M | 2,254,841 |
| John W. Childs Director | Apr 22, 2024 | Buy | +97,560 | $41.00 | $4.00M | 4,096,512 |
| Gregory Bailey Director | Apr 22, 2024 | Buy | +48,780 | $41.00 | $2.00M | 1,574,568 |
| Vlad Coric Chief Executive Officer, Director | Apr 5, 2024 | Award | +231 | – | – | 840,890 |
| Vlad Coric Chief Executive Officer, Director | Apr 5, 2024 | Award | +232 | – | – | 1,666,466 |
| Vlad Coric Chief Executive Officer, Director | Apr 5, 2024 | Award | +231 | – | – | 407,213 |
| John W. Childs Director | Apr 5, 2024 | Award | +2,091 | – | – | 2,181,671 |
| Vlad Coric Chief Executive Officer, Director | Mar 8, 2024 | Award | +2,155 | – | – | 840,659 |
| Vlad Coric Chief Executive Officer, Director | Mar 8, 2024 | Award | +2,155 | – | – | 406,982 |
| Vlad Coric Chief Executive Officer, Director | Mar 8, 2024 | Award | +2,162 | – | – | 1,666,234 |
| John W. Childs Director | Mar 8, 2024 | Award | +19,412 | – | – | 2,179,580 |
| John W. Childs Director | Jan 8, 2024 | Other | +48,505 | – | – | 2,160,168 |
| Vlad Coric Chief Executive Officer, Director | Jan 8, 2024 | Award | +5,384 | – | – | 404,827 |
| Vlad Coric Chief Executive Officer, Director | Jan 8, 2024 | Award | +5,384 | – | – | 838,504 |
| Vlad Coric Chief Executive Officer, Director | Jan 8, 2024 | Award | +5,400 | – | – | 1,662,431 |
Awards, option exercises, tax withholding and gifts are shown alongside open-market buys and sales. Each name links to the filing on SEC EDGAR.
Planned insider sales
Notices of proposed sale filed on Form 144 before shares are sold
| Seller | Filed | Shares | Market value | Planned sale | Acquired through |
|---|---|---|---|---|---|
| Irina Antonijevic Director | Dec 29, 2023 | 11,000 | $459.66K | Dec 29, 2023 | STOCK OPTION EXERCISE |